Novel Group Format Helps Underserved Diabetics
Increased rates of retinopathy screening, foot examinations, and kidney function testing observed.
Print Issue: September 01, 2010
Study: Interpreters Improve Satisfaction with ED Visits
A recent study reveals that non-English speaking patients who are provided with a professional interpreter in the emergency department (ED) of a hospital are far more likely to be satisfied with the experience and to understand information from health care professionals.
New York Hospitals Test Malpractice Pilot Program
Five New York hospitals will participate in a federally funded pilot program designed to cut back on medical malpractice costs.
Wisconsin Ordered to Repay Medical Malpractice Fund
The Wisconsin Supreme Court recently ruled that the state must repay $200 million that was taken from a medical malpractice fund three years ago to balance the state budget.
Genes Correlate with RCC Recurrence Risk
CHICAGO—Researchers at Cleveland Clinic, in collaboration with Genomic Health, Inc. and Pfizer, say they have demonstrated for the first time a strong correlation between gene expression and risk of disease recurrence in patients with early-stage renal cell carcinoma (RCC).
Imaging Approach May Distinguish Clear Cell Renal Cell Carcinoma
SAN FRANCISCO—For the first time, clinicians may have an imaging tool that can help distinguish clear cell renal cell carcinoma (RCC) from other kinds of renal masses.
DVA/DoD Has Highest Arteriovenous Fistula Use
Patients who initiate hemodialysis (HD) within the Department of Veterans Affairs/Department of Defense (DVA/DoD) system are more likely to start treatment with an arteriovenous fistula (AVF) than patients with other types of insurance coverage, including Medicare, a study found.
Second-Look Nephroscopy Boosts Stone-Free Rate
CHARLOTTETOWN, Canada—Second-look nephroscopy improves the stone-free rate in patients with renal calculi undergoing single-tract percutaneous nephrolithotomy (PCNL), according to a study presented at the Canadian Urological Association’s 2010 annual meeting.
Drug Shows Promise for Castration-Resistant Prostate Cancer
CHICAGO—Alpharadin, an investigational agent, may relieve pain and improve survival in men with metastatic castration-resistant prostate cancer (CRPC), according to data presented at the American Society of Clinical Oncology annual meeting.
For Locally Advanced Prostate Cancer, Add Radiation
ADT plus radiation should be the standard treatment approach, new research says.
